These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 12083037)

  • 21. Costs associated with combination antiretroviral therapy in HIV-infected patients.
    Yazdanpanah Y
    J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing resource allocation for HIV/AIDS prevention programmes: an analytical framework.
    Bautista-Arredondo S; Gadsden P; Harris JE; Bertozzi SM
    AIDS; 2008 Jul; 22 Suppl 1():S67-74. PubMed ID: 18664956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Socio-economic impact of antiretroviral treatment in HIV patients. An economic review of cost savings after introduction of HAART.
    Gonzalo T; García Goñi M; Muñoz-Fernández MA
    AIDS Rev; 2009; 11(2):79-90. PubMed ID: 19529748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The price of HIV treatment.
    Brinkman K
    Neth J Med; 2003 Dec; 61(12):391-2. PubMed ID: 15025413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The oncology impact of highly active antiretroviral therapy.
    Schlichemeyer R; Chambers C; Gill MJ
    J Oncol Pharm Pract; 2007 Mar; 13(1):17-25. PubMed ID: 17621563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).
    Beck EJ; Mandalia S; Youle M; Brettle R; Fisher M; Gompels M; Kinghorn G; McCarron B; Pozniak A; Tang A; Walsh J; Williams I; Gazzard B
    Int J STD AIDS; 2008 May; 19(5):297-304. PubMed ID: 18482958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The president's fiscal year 2007 initiative for human immunodeficiency virus counseling and testing expansion in the United States: a scenario analysis of its coverage, impact, and cost-effectiveness.
    Holtgrave DR
    J Public Health Manag Pract; 2007; 13(3):239-43. PubMed ID: 17435490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV/AIDS prevention and treatment.
    Piot P; Zewdie D; Türmen T
    Lancet; 2002 Jul; 360(9326):86; author reply 87-8. PubMed ID: 12114063
    [No Abstract]   [Full Text] [Related]  

  • 29. Study: HAART less costly than treatment for AIDS. Annual health care cost lowered by 31%.
    AIDS Alert; 2001 Feb; 16(2):26-7. PubMed ID: 15446225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Highly active antiretroviral therapy (HAART)--plus: next steps to enhance HAART in resource-limited areas?
    Flanigan TP; Wools-Kaloustain K; Harwell J; Cu-Uvin S; Kimaiyo S; Carter EJ
    Clin Infect Dis; 2007 Dec; 45(11):1499-501. PubMed ID: 17990234
    [No Abstract]   [Full Text] [Related]  

  • 31. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India.
    Kumarasamy N; Solomon S; Chaguturu SK; Cecelia AJ; Vallabhaneni S; Flanigan TP; Mayer KH
    Clin Infect Dis; 2005 Nov; 41(10):1525-8. PubMed ID: 16231268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART.
    Stoll M; Claes C; Schulte E; Graf von der Schulenburg JM; Schmidt RE
    Eur J Med Res; 2002 Nov; 7(11):463-71. PubMed ID: 12568973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
    Krentz HB; Auld MC; Gill MJ;
    CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
    Tonwe-Gold B; Ekouevi DK; Viho I; Amani-Bosse C; Toure S; Coffie PA; Rouet F; Becquet R; Leroy V; El-Sadr WM; Abrams EJ; Dabis F
    PLoS Med; 2007 Aug; 4(8):e257. PubMed ID: 17713983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly active antiretroviral therapy and tuberculosis control in Africa: synergies and potential.
    Harries AD; Hargreaves NJ; Chimzizi R; Salaniponi FM
    Bull World Health Organ; 2002; 80(6):464-9. PubMed ID: 12132003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The fidelity of decision-making: the Achilles heel for the successful implementation of prevention modalities for HIV.
    Tramont EC
    AIDS; 2010 Apr; 24(7):1077-8. PubMed ID: 20386377
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-effectiveness of services for sexually transmitted diseases in prevention of HIV-1.
    O'Farrell N
    Lancet; 1998 Feb; 351(9103):681-2. PubMed ID: 9500368
    [No Abstract]   [Full Text] [Related]  

  • 39. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.
    Montaner JS; Hogg R; Wood E; Kerr T; Tyndall M; Levy AR; Harrigan PR
    Lancet; 2006 Aug; 368(9534):531-6. PubMed ID: 16890841
    [No Abstract]   [Full Text] [Related]  

  • 40. Budget increases for AIDS.
    AIDS Patient Care STDS; 1999 Jan; 13(1):1. PubMed ID: 11362079
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.